Erika Nardini Sells 198 Shares of Axon Enterprise (NASDAQ:AXON) Stock

Axon Enterprise, Inc (NASDAQ:AXON) Director Erika Nardini sold 198 shares of the stock in a transaction that occurred on Tuesday, March 17th. The stock was sold at an average price of $506.58, for a total value of $100,302.84. Following the sale, the director owned 1,946 shares in the company, valued at $985,804.68. The trade was a 9.24% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this link.

Axon Enterprise Trading Down 1.2%

Shares of NASDAQ AXON opened at $502.18 on Friday. Axon Enterprise, Inc has a 12-month low of $396.41 and a 12-month high of $885.91. The company has a market cap of $40.38 billion, a price-to-earnings ratio of 330.38, a price-to-earnings-growth ratio of 10.85 and a beta of 1.46. The company has a current ratio of 2.53, a quick ratio of 2.29 and a debt-to-equity ratio of 0.53. The stock’s 50 day simple moving average is $522.19 and its 200 day simple moving average is $603.07.

Axon Enterprise (NASDAQ:AXON) last issued its quarterly earnings data on Tuesday, February 24th. The biotechnology company reported $2.15 EPS for the quarter, topping analysts’ consensus estimates of $1.60 by $0.55. The firm had revenue of $796.72 million during the quarter, compared to the consensus estimate of $755.29 million. Axon Enterprise had a return on equity of 2.82% and a net margin of 4.48%.The firm’s revenue was up 38.5% on a year-over-year basis. During the same period in the prior year, the business earned $2.08 EPS. Equities research analysts expect that Axon Enterprise, Inc will post 5.8 EPS for the current year.

Axon Enterprise News Roundup

Here are the key news stories impacting Axon Enterprise this week:

• Positive Sentiment: Strong software/subscriptions momentum — Coverage highlights AXON’s Software & Services revenue rising ~40% in 2025, supporting a higher‑margin recurring‑revenue thesis that underpins long‑term earnings leverage. Axon’s Software & Services Strength in Focus
• Positive Sentiment: Municipal procurement tailwinds — A $1.97M grant for Decatur police tech signals continued local government demand for public‑safety hardware + software, a core end‑market for Axon. Decatur grant
• Positive Sentiment: Institutional interest / positive narratives — Fund mentions and “trending” writeups (e.g., Baron Opportunity Fund coverage) can attract flows and broaden investor attention. Baron Fund mention
• Neutral Sentiment: Marketwatch / trending coverage — Aggregator pieces note AXON’s relative performance versus peers; useful for awareness but not a direct fundamental catalyst. MarketWatch piece
• Neutral Sentiment: Short‑interest reporting appears unreliable — March short‑interest posts show “0 shares” and NaN changes, likely a reporting glitch rather than a real change in short pressure; treat as noisy data until exchanges clarify.
• Negative Sentiment: Insider selling — Director Erika Nardini sold 198 shares (~$506.58 avg) and Director Jeri Williams sold 157 shares; small absolute amounts but can feed short‑term profit‑taking narratives. Nardini SEC filing Williams SEC filing
• Negative Sentiment: Market skepticism / multiple compression — Recent commentary (SaaS‑sector rotation and pieces questioning Axon’s growth premium) plus analyst target trims have contributed to short‑term selling pressure. Forbes — growth story debate

Wall Street Analysts Forecast Growth

Several brokerages recently weighed in on AXON. Royal Bank Of Canada cut their price objective on shares of Axon Enterprise from $860.00 to $735.00 and set an “outperform” rating on the stock in a research report on Wednesday, February 25th. UBS Group dropped their price target on shares of Axon Enterprise from $610.00 to $570.00 and set a “neutral” rating on the stock in a research note on Wednesday, February 25th. Robert W. Baird set a $800.00 price target on Axon Enterprise in a report on Wednesday, February 25th. Northcoast Research upgraded Axon Enterprise from a “neutral” rating to a “buy” rating and set a $742.00 price objective for the company in a research report on Tuesday, January 6th. Finally, Craig Hallum reissued a “buy” rating and issued a $820.00 price objective on shares of Axon Enterprise in a report on Wednesday, February 25th. Sixteen analysts have rated the stock with a Buy rating and three have given a Hold rating to the company’s stock. According to data from MarketBeat, Axon Enterprise presently has a consensus rating of “Moderate Buy” and a consensus target price of $762.93.

Hedge Funds Weigh In On Axon Enterprise

Institutional investors and hedge funds have recently bought and sold shares of the stock. Vanguard Group Inc. lifted its stake in shares of Axon Enterprise by 0.6% in the 4th quarter. Vanguard Group Inc. now owns 9,367,224 shares of the biotechnology company’s stock worth $5,319,928,000 after acquiring an additional 53,060 shares during the period. Geode Capital Management LLC increased its stake in shares of Axon Enterprise by 1.6% during the fourth quarter. Geode Capital Management LLC now owns 2,226,159 shares of the biotechnology company’s stock valued at $1,265,657,000 after acquiring an additional 35,544 shares during the period. Baillie Gifford & Co. raised its holdings in Axon Enterprise by 1,198.7% during the fourth quarter. Baillie Gifford & Co. now owns 1,642,578 shares of the biotechnology company’s stock worth $932,869,000 after purchasing an additional 1,516,099 shares in the last quarter. Sands Capital Management LLC raised its holdings in Axon Enterprise by 11.6% during the fourth quarter. Sands Capital Management LLC now owns 1,609,436 shares of the biotechnology company’s stock worth $914,047,000 after purchasing an additional 167,095 shares in the last quarter. Finally, Wellington Management Group LLP lifted its position in Axon Enterprise by 326.9% in the fourth quarter. Wellington Management Group LLP now owns 1,539,738 shares of the biotechnology company’s stock worth $874,463,000 after purchasing an additional 1,179,038 shares during the period. Institutional investors own 79.08% of the company’s stock.

Axon Enterprise Company Profile

Axon Enterprise, Inc develops technology and weapons systems for public safety and law enforcement agencies, combining hardware, software and cloud services. The company’s hardware portfolio includes conducted energy weapons (commonly known as TASER devices), body-worn cameras and in-car camera systems. Axon pairs these devices with a suite of connected products and accessories designed to capture, store and manage field evidence.

Beyond hardware, Axon operates a subscription-based software platform for digital evidence management, evidence review and records management.